Results 51 to 60 of about 338,912 (243)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Sipa1 deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.

Blood Advances, 2018
Mutations of signal-induced proliferation-associated gene 1 (SIPA1), a RAP1 GTPase-activating protein, were reported in patients with juvenile myelomonocytic leukemia, a childhood myelodysplastic/myeloproliferative neoplasm (MDS/MPN). Sipa1 deficiency in
P. Xiao, M. Dolinska, L. Sandhow, M. Kondo, A. Johansson, T. Bouderlique, Ying Zhao, Xidan Li, M. Dimitriou, G. Rassidakis, E. Hellström-Lindberg, N. Minato, J. Walfridsson, D. Scadden, M. Sigvardsson, H. Qian   +15 more
semanticscholar   +1 more source

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation

Clinical Pharmacology &Therapeutics, EarlyView.
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian, Yalin Yin, Rong Chen, Junsheng Xue, Jianbo Gu, Zhengfang Du, Ruoyi He, Tianyan Zhou   +7 more
wiley   +1 more source

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Journal of Clinical Investigation, 2018
Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor ...
A. McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, B. Spitzer, A. Intlekofer, Jihae Ahn, K. Shank, Franck Rapaport, Minal A. Patel, Efthymia Papalexi, A. Shih, A. Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, R. Nagaraja, K. Yen, J. Teruya-Feldstein, Kwok-kin Wong, R. Rampal, M. V. Heiden, C. Thompson, R. Levine   +22 more
semanticscholar   +1 more source

Case Report: Free-Floating Intracoronary Thrombus: Who Is the Convict?

Frontiers in Oncology, 2022
In young patients, especially with no traditional coronary risk factors, hypercoagulable states may always be considered as an alternative cause of acute coronary syndromes.
Francesca Mantovani, Ambra Paolini, Andrea Barbieri, Giuseppe Boriani   +3 more
doaj   +1 more source

Monocyte maturation pattern by flow cytometry expression of CD64, CD300e, and CD14 correlates to presence of myeloid neoplasm and helps identify blast equivalents in the setting of monocytic neoplasm

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract CD300e is a marker of mature monocytes in flow cytometry; however, there is limited detailed information on staining patterns in conjunction with other monocyte markers. We evaluated the flow cytometric staining patterns of CD64, CD14, and CD300e in 12 negative and 33 positive peripheral blood specimens and 16 negative and 56 positive bone ...
Jenny Zhang, Jacob Kaplan, Elizabeth Courville   +2 more
wiley   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

Environmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons, Marc A. Beal, Kerry L. Dearfield, George R. Douglas, Min Gi, B. Bhaskar Gollapudi, Robert H. Heflich, Katsuyoshi Horibata, Michelle Kenyon, Alexandra S. Long, David P. Lovell, Anthony M. Lynch, Meagan B. Myers, Stefan Pfuhler, Alisa Vespa, Andreas Zeller, George E. Johnson, Paul A. White   +17 more
wiley   +1 more source

Extramedullary hematopoiesis in the absence of myeloproliferative neoplasm: Mayo Clinic case series of 309 patients

Blood Cancer Journal, 2018
Background : Extramedullary hematopoiesis (EMH) implies the production of erythroid and myeloid progenitor cells outside of the bone marrow. EMH in adults is typically seen in patients with myeloproliferative neoplasms (MPN).
N. Fan, S. Lavu, C. Hanson, A. Tefferi
semanticscholar   +1 more source

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome

Clinical Medicine Insights: Case Reports, 2018
Hydroxyurea (HU) is a drug frequently used in the treatment of chronic myeloproliferative neoplasms. The most common side effects of this drug are pancytopenia, digestive and skin disorders.
Oriol Plans Galván, Hipólito Pérez Moltó, Ariadna Fabià-Mayans, Blanca Xicoy, José Luis Mate, Pilar Ricart Martí   +5 more
doaj   +1 more source

Single-cell analysis based dissection of clonality in myelofibrosis

Nature Communications, 2020
Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
Elena Mylonas, Kenichi Yoshida, Mareike Frick, Kaja Hoyer, Friederike Christen, Jaspal Kaeda, Matthias Obenaus, Daniel Noerenberg, Cornelius Hennch, Willy Chan, Yotaro Ochi, Yuichi Shiraishi, Yusuke Shiozawa, Thorsten Zenz, Christopher C. Oakes, Birgit Sawitzki, Michaela Schwarz, Lars Bullinger, Philipp le Coutre, Matthew J. J. Rose-Zerilli, Seishi Ogawa, Frederik Damm   +21 more
doaj   +1 more source